BioSpace News Archive

Thermo Fisher Scientific today announced the launch of the Gibco™ Cell Therapy Systems (CTS™) Cellmation™ Software , a first-of-its-kind automation solution designed to connect and integrate workflows across multiple Thermo Fisher Scientific cell therapy instruments while enabling cGMP compliance.

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors.

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced a Trial in Progress poster presentation on the Phase 1/2 (AMPLIFY-7P) study design at the ASCO Gastrointestinal Cancers (“ASCO GI”) Symposium being held January 18-20, 2024 in San Francisco, CA.

NurExone Biologic Inc., a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to share several updates.

Bolden Therapeutics, Inc. today announced the closing of their $1.5M pre-seed convertible note financing.

New Head of Product and COO to drive innovation, growth, and efficiency across drug discount management for drug manufacturers, states, and safety-net providers

Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV) today announced the appointment of Jeff Bennett as Chief Strategy and Innovation Officer and Seth Ravine as Chief Commercial Officer, effective December 2023.

TRxADE HEALTH, INC. announced that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2023.

Leaders at City of Hope forecast that in 2024 more people will benefit from cancer breakthroughs, including research that unlocks the biology behind cancer disparities, wider access to CAR T cell therapy and rapid whole genome sequencing.

Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, today announced positive top line results from the Phase 2a trial with IPL344 in amyotrophic lateral sclerosis (ALS) patients.